HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B

M. Pawłowska · W. Halota · E. Smukalska · T. Woźniakowska-Gęsicka · J. Kupś

Received: 2 February 2011 / Accepted: 5 July 2011 / Published online: 29 July 2011
© The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract The aim of this study was to assess HBV DNA suppression after 24 weeks of treatment with entecavir in previously treated children with CHB. Thirty children aged 5–17 years (25 males and 5 females) with CHB were treated with entecavir 0.5 or 1 mg daily. Twenty-two children were HBeAg-positive, eight were HBeAg-negative, and in eight HBV polymerase mutations were detected. After 24 weeks of treatment, mean and median HBV DNA levels and ALT activity were lower versus baseline, overall and in both subgroups. The overall median HBV DNA level decreased from 1.2 x 10^7 IU/mL to 3.3 x 10^2 IU/mL (p < 0.000004), in HBeAg-positive from 7.8 x 10^7 IU/mL to 6.3 x 10^3 IU/mL (p < 0.00004), and in HBeAg-negative from 2.5 x 10^4 IU/mL to 5.0 x 10^1 IU/mL (p < 0.03). The serum HBV DNA disappearance was observed in 7/8 (88%) HBeAg-negative and in 5/22 (23%) HBeAg-positive patients. The overall mean ALT activity decreased from 164±290 U/L to 34.1±18.9 U/L (p < 0.00007), in HBeAg-positive from 214±326 U/L to 38.5±19.2 U/L (p < 0.000074), and in HBeAg-negative from 27±14 U/L to 20±8 U/L (p < 0.03). Twenty-four weeks of treatment with entecavir results in suppression of HBV DNA in a substantial proportion of children previously treated ineffectively with CHB.

Introduction

In the time of common anti-HBV vaccination, children at risk for HBV infection include those who were not vaccinated, had an inadequate response to vaccination, were exposed prior to being vaccinated, were born to HBV-infected mothers but did not receive active/passive immunoprophylaxis or this immunoprophylaxis was ineffective [1]. Chronic hepatitis B in children is mostly asymptomatic, but they are at risk for severe complications like liver cirrhosis and hepatocellular carcinoma (HCC).

Individuals who acquire the virus vertically during childbirth or at a young age are the priority for effective treatment. The current goals of treatment are: suppression of viral replication to undetectable HBV DNA levels, ALT level normalisation, HBe/anti HBe seroconversion, an improvement in liver histology and preventing liver complications by reducing the risk of progressive liver disease.

Anti-HBV therapies approved for adults include interferon alpha, an immune modulator and nucleoside/nucleotide analogues that suppress viral replication [2, 3]. Treatment options for children with chronic hepatitis B are limited. In Poland, standard anti-HBV therapy in children now includes only recombinant interferon.

The aim of this study was to assess the HBV DNA suppression after 24 weeks of treatment with entecavir of
previously treated children and adolescents with chronic hepatitis B (CHB).

**Materials and methods**

Thirty children with chronic hepatitis B, who did not respond to previous anti-HBV therapy were included in treatment with entecavir. There were 25 males and five females in the group, aged 5–17 years (mean age 15.3±2.34). Twenty-two children were HBeAg-positive and eight were HBeAg-negative. Seven children had previously been treated with recombinant interferon (IFN), two with lamivudine (LAM), one with adefovir (ADV), 19 with IFN and LAM, and one with IFN, LAM and ADV.

Baseline HBV DNA viral load was >10^7 IU/mL in 15 children, between 10^6 and 10^7 IU/mL in three patients, between 10^5 and 10^6 in three, between 10^4 and 10^5 IU/mL in seven and between 10^3 and 10^4 IU/mL in two children. In eight children, HBV polymerase mutations L180M and M204V were detected, and L80I and M204I in one.

All children had a liver biopsy and liver ultrasound as a prerequisite to enrolment and treatment. Liver biopsy specimens were scored according to the modified Scheuer scale and were assigned a grade for necroinflammation between 0 and 4 and a stage between 0 and 4 for fibrosis [4]. No child had liver disease assessed greater than grade 2, stage 2.

In the examined group there were no patients with histological evidence of hepatocellular carcinoma or chronic liver disease other than CHB. Patients co-infected with hepatitis C virus or human immunodeficiency virus were not eligible for treatment.

Children and adolescents included in the study received entecavir in the dose 0.5 or 1 mg daily.

The protocol was approved by the ethics committee of Collegium Medicum Nicolaus Copernicus University in Bydgoszcz, Poland. Informed consent was provided in writing by the legal guardian of each patient and each child older than 12 years before treatment was initiated.

During treatment patients were required to return to the clinic at regular intervals at which time blood samples were obtained for determination of serum HBV DNA, HBeAg, HBsAg, and ALT activity. A complete blood count was performed at each clinic visit.

Serum HBV DNA was determined at baseline and at week 24 by quantitative polymerase chain reaction assay (COBAS® AmpliPrep/COBAS TaqMan® HBV Test, limit of quantitation=55 IU/mL; limit of detection 12 IU/mL [Roche Diagnostics]).

In 24 patients serum HBV DNA was assessed at weeks 4 and 12 during therapy.

Safety was monitored at each clinic visit by means of laboratory tests, physical examination and adverse events reported by the patient or guardian.

**Statistical analysis**

Serum HBV DNA levels, ALT activity, grading and staging were analysed by descriptive statistics. Means and standard errors were calculated for each group and for the entire sample. Wilcoxon’s test was used to test the differences between baseline and after 24 weeks of treatment.

### Table 1: Baseline characteristics of patients

| Characteristic                  | HBeAg-positive (n=22) | HBeAg-negative (n=8) | All patients (n=30) |
|--------------------------------|-----------------------|----------------------|--------------------|
| Age (years), mean±SD (range)   | 15.3±2.68             | 15.3±1.04            | 15.3±2.34          |
| Male : female                  | 3 : 2                 | 6 : 2                | 9 : 4              |
| HBV DNA, IU/ml, mean±SD        | 8.1x10^7±9.7x10^7     | 3.5x10^4±2.9x10^4    | 6.1x10^7±9.1x10^7  |
| Serum ALT (IU/L), mean±SD      | 214±326               | 27±14.04             | 164±290            |
| Fibrosis stage, mean (range)   | 2 (1–2)               | 1.57 (0–2)           | 2 (0–2)            |
| Necroinflammatory grade, mean (range) | 2 (1–2) | 1.86 (1–2) | 2 (1–2) |

*Upper limit of normal: females 31 IU/l; males 40 IU/l*

### Table 2: Serum HBV DNA (IU/mL) level and ALT activity after 24 weeks of treatment vs. baseline in examined patients

| Measure                   | Baseline | After 24 weeks of treatment | p (Wilcoxon’s test) |
|---------------------------|----------|-----------------------------|---------------------|
|                           | Mean±SD  | Median                      | Mean±SD             | Median |          |
| Serum HBV DNA (IU/mL)     | 61088601±91363098 | 12000000                  | 69547±223304       | 326    | 0.000004 |
|                           | Min 1000 | Max 410000000               | Min 0.0000          | Max 1100000 |          |
| ALT activity (U/L)        | 164±290  | 60                          | 34.10±18.9          | 30     | 0.000007 |
deviations and median values and interquartile ranges were calculated for values collected at baseline and in week 24. To compare those results in HBeAg positive and HBeAg negative patients, the U Mann-Whitney’s and Wilcoxon’s tests were used.

**Results**

The baseline characteristics of the patients are presented in Table 1.

In all patients we observed the increased ALT activity values during the 2 years prior to treatment, although ALT within normal limits was recorded at the start of entecavir treatment in eight patients. No child had severe liver disease assessed as greater than grade 2, stage 2 on the pretreatment liver biopsy but had at least grade 1 and/or stage 1 at baseline.

Mean baseline serum HBV DNA level and ALT activity were statistically significantly lower in HBeAg-negative patients in comparison to HBeAg-positive ($p<0.0003$ and $p<0.0006$, respectively).

HBV DNA levels and ALT activity decreased in all patients during treatment with entecavir.

After 24 weeks of treatment, mean and median HBV DNA levels and ALT activity were lower than the baseline value, overall and in the HBeAg-positive and HBeAg-negative subgroups. The overall median HBV DNA level decreased from $1.2 \times 10^7$ IU/mL at baseline to $3.3 \times 10^5$ IU/mL after 24 weeks of treatment ($p<0.000004$). In HBeAg-positive patients the median HBV DNA level decreased from $7.8 \times 10^7$ IU/mL at baseline to $6.3 \times 10^3$ IU/mL ($p<0.000004$), and in HBeAg-negative from $2.5 \times 10^9$ IU/mL to $5.0 \times 10^5$ IU/mL, respectively ($p<0.03$) (Tables 2, 3, 4).

Mean serum HBV DNA level and ALT activity after 24 weeks of treatment were statistically significantly lower in HBeAg-negative patients in comparison to HBeAg-positive (respectively, $p<0.002$ and $p<0.005$).

After 24 weeks of treatment serum HBV DNA was undetectable in 12 patients: The serum HBV DNA disappearance was observed in seven of the eight (88%) HBeAg-negative patients, and in five of the 22 (23%) HBeAg-positive. Among seven HBeAg negative patients with undetectable HBV DNA after 24 weeks of therapy, six were with normal ALT activity while one patient was with increased ALT activity at baseline. In all five HBe-positive patients with HBV DNA disappearance after 24 weeks of entecavir therapy the baseline ALT activity was increased.

In six patients with HBV DNA disappearance, serum HBV DNA was undetectable from the 5th week of treatment. Among them there were five HBeAg-negative and one HBeAg-positive patients at baseline. Until the 24th week of therapy we did not observe HBe/anti-HBe seroconversion in this and other patients who were HBeAg-positive at baseline.

The overall mean ALT activity decreased from $164 \pm 290$ U/L at the baseline to $34.1 \pm 18.9$ U/L after 24 weeks of entecavir therapy ($p<0.000007$). In HBeAg-positive patients the mean ALT activity decreased from $214 \pm 326$ U/L to $38.59 \pm 19.2$ U/L ($p<0.000074$) and in HBeAg-negative patients from $27 \pm 14$ U/L to $20 \pm 8$ U/L ($p<0.03$), respectively.

During the period analyzed we did not observe any adverse events of entecavir therapy.

**Discussion**

Treatment of children with chronic hepatitis B seems to be controversial. Some authors declare that most HBV infected children will remain in the immune tolerant

| Measure                      | Baseline                  | After 24 weeks of treatment | $p$  |
|------------------------------|----------------------------|-----------------------------|------|
|                              | Mean±SD | Median | Mean±SD | Median |      |
| Serum HBV DNA (IU/mL)        | 35491±29886 | 25000  | 69±51 | 50    | 0.027709 |
| Min 6840                     | Max 96200   |                    |       |       |      |
| ALT activity (U/L)           | 27±14 | 21     | 20±8 | 19    | 0.027709 |
The results of this pilot study show that a 24-week course of entecavir therapy in children and adolescents can produce suppression of HBV DNA replication in HBeAg-positive and HBeAg-negative individuals, previously treated ineffectively with anti-HBV. After 24 weeks of entecavir treatment the serum HBV DNA decreased in all treated patients. The serum HBV DNA disappearance was observed in seven of the eight (88%) HBeAg-negative patients, and in five of the 22 (23%) HBeAg-positive.

These results are clinically significant because HBV DNA levels correlate with an increased risk of liver disease. There is a linear relationship between the serum concentration of HBV DNA and the long-term risk of cirrhosis and hepatocellular carcinoma in patients with CHB [6–8]. Effective treatment is particularly important in children with CHB, because the virus cannot be eradicated and, as a result, complications can evolve over many decades in these individuals.

In five of the six patients with HBV DNA disappearance after 24 weeks of therapy, undetectable levels of HBV DNA were observed after the initial 4 weeks of therapy (RVR). It seems that early disappearance of HBV viremia may be a predictor of beneficial treatment response. Sustained suppression of HBV DNA replication results in histological improvement, normalization of ALT levels and, in some patients with HBeAg-positive disease, seroconversion to an anti-HBe state [9–11]. Treatment with entecavir decreasing HBV DNA replication induced the biochemical and histological improvement of liver disease in adults [12, 13].

In the examined patients, treatment with entecavir was well tolerated. There were no unusual safety issues emerging in this population and the safety profile was similar to that seen in adult populations. We did not observe ALT flares and entecavir resistance mutations.

In conclusion, the results of this pilot study show that 24 weeks of treatment with entecavir results in suppression of HBV DNA in a substantial proportion of children previously treated ineffectively with CHB. Larger and longer trials are now required to better define the magnitude of the benefit in this population.

Open Access  This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Ngui SL, Andrews NJ, Underhill GS et al (1998) Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin Infect Dis 27:100–106
2. Keeffe EB, Dieterich DT, Han SH et al (2008) A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 6:1315–1341
3. European Association for the Study of the Liver (2009) EASL Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50:227–242
4. Gabriel A, Mietkiewski J, Ziolkowski A (1999) Current morphological classification of chronic liver inflammation: its merits and problems. Pol J Pathol 50(4 Suppl 1):5–11
5. Jonas MM, Block JM, Haber BA et al (2010) Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology 52:2192–2205
6. Chen CJ, Yang HI, Su J et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65–73
7. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678–686
8. Yang HI, Lu SN, Liaw YF et al (2002) Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347:168–174
9. Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45:507–539
10. Iorio R, Giannattasio A, Cirillo F, D’Al A, Vegnente A (2007) Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis 45:943–949
11. Bortolotti F, Guido M, Bartolacci S et al (2006) Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 43:556–562
12. Chang TT, Lai CL, Yoon SK et al (2010) Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatol 51:422–430
13. Chang TT, Liaw YF, Wu SS et al (2010) Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52(3):886–893